- Home
- RIGL vs IBTA Comparison
RIGL vs IBTA Comparison
Compare RIGL & IBTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | IBTA |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.9M | 830.3M |
| IPO Year | 2000 | 2024 |
Fundamental Metrics
Financial Performance| Metric | RIGL | IBTA |
|---|---|---|
| Price | $49.17 | $43.11 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 9 |
| Target Price | ★ $63.00 | $36.14 |
| AVG Volume (30 Days) | ★ 194.5K | 180.3K |
| Earning Date | 11-03-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | $294,282,000.00 | ★ $342,389,000.00 |
| Revenue This Year | $3.89 | $3.20 |
| Revenue Next Year | $21.95 | $8.88 |
| P/E Ratio | $36.91 | ★ N/A |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $19.10 |
| 52 Week High | $52.24 | $43.43 |
Technical Indicators
Market Signals| Indicator | RIGL | IBTA |
|---|---|---|
| Relative Strength Index (RSI) | 59.28 | 63.85 |
| Support Level | $33.93 | $35.30 |
| Resistance Level | $49.50 | $43.43 |
| Average True Range (ATR) | 1.86 | 1.71 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 74.01 | 85.55 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About IBTA Ibotta Inc.
Ibotta Inc operates a digital promotions platform, the Ibotta Performance Network (IPN), which connects consumer packaged goods (CPG) brands with consumers through a network of publishers. It sources digital offers from clients and distributes them via its technology platform, earning revenue when promotions result in consumer transactions. The platform supports offers across grocery and general merchandise categories, including toys, clothing, beauty, electronics, pet, and home products. The majority of its revenues is derived from the fees charged to clients when consumers redeem offers on the IPN by purchasing promoted products.